Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases.
about
The Role of the Transcriptional Regulation of Stromal Cells in Chronic InflammationTargeting TNF receptors in rheumatoid arthritisMurine models of inflammatory bowel disease (IBD): challenges of modeling human diseaseRedeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel diseaseThe control of inflammation via the phosphorylation and dephosphorylation of tristetraprolin: a tale of two phosphatasesWhole-body deletion of LPS-induced TNF-α factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritisInteraction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.Inflammatory bowel diseaseHigher Levels of Secretory IgA Are Associated with Low Disease Activity Index in Patients with Reactive Arthritis and Undifferentiated SpondyloarthritisTNF-α stimulates colonic myofibroblast migration via COX-2 and Hsp27Extensive phenotypic characterization of a new transgenic mouse reveals pleiotropic perturbations in physiology due to mesenchymal hGH minigene expression.IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritisMolecular control of steady-state dendritic cell maturation and immune homeostasis.A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritisIntestinal dendritic cells in the pathogenesis of inflammatory bowel disease.Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.Small intestine inflammation in Roquin-mutant and Roquin-deficient mice.TNF-α and LPA promote synergistic expression of COX-2 in human colonic myofibroblasts: role of LPA-mediated transactivation of upregulated EGFR.Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathologyTNF-α potentiates lysophosphatidic acid-induced COX-2 expression via PKD in human colonic myofibroblasts.Intestinal myofibroblasts: targets for stem cell therapyIntestinal stricture in Crohn's disease.Tristetraprolin (TTP) coordinately regulates primary and secondary cellular responses to proinflammatory stimuliProtein kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and bradykinin in human colonic myofibroblasts.Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.Remission of collagen-induced arthritis through combination therapy of microfracture and transplantation of thermogel-encapsulated bone marrow mesenchymal stem cells.Inflammatory bowel disease associated arthropathyProlonged tumor necrosis factor α primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin.Inflammation, Innate Immunity, and the Intestinal Stromal Cell Niche: Opportunities and Challenges.A Feedback Loop between Inflammation and Zn Uptake.Spontaneous retrotransposon insertion into TNF 3'UTR causes heart valve disease and chronic polyarthritis.TNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts.Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance.Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis.IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer.Mesenchymal stem cells can improve anal pressures after anal sphincter injury.Nuclear factor-κB modulates osteogenesis of periodontal ligament stem cells through competition with β-catenin signaling in inflammatory microenvironments.CollagenVI-Cre mice: A new tool to target stromal cells in secondary lymphoid organs.Protein kinase D mediates synergistic expression of COX-2 induced by TNF-{alpha} and bradykinin in human colonic myofibroblasts.Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum.
P2860
Q26778930-0200B183-DDEA-45CC-B2B4-CB403D49C8EAQ26853279-F5A7B097-363D-45EA-8C1A-13B3B693DFABQ26863622-1EF452CC-B25B-4898-9CEB-D0DD72AF10EDQ27027630-911A0779-0218-46B9-82EA-8A2404E5D887Q28076811-E08B7E95-588F-48A2-A5C9-B2BFE9EEE621Q28511199-592FD346-3369-4997-8717-30C3C8F5A831Q29417082-D9B609F6-95B2-43FA-A100-DF469E5AE241Q29615500-6C6D18EC-E99A-426E-88AD-CE1797A67C1DQ32115630-E2AACBCF-4404-47B5-9168-D0B30CBE1029Q33565290-434BDE89-2E32-48E2-84BC-F3E240151A46Q33729165-4AA56070-E32F-4FC0-854F-17C97E2AB683Q33769303-4A46DF0E-8281-4150-A0C4-83837331C110Q33882051-DF4A87E4-9F37-488A-88DF-51E9C7F91ADAQ33923409-0E151EEE-06C3-4B89-9A83-5C702AF0A218Q34222959-B780059E-D6BA-46D9-B16E-FA392D903DF2Q34441916-4FEE4109-FE4F-4378-AC58-A400EBAB596FQ34602347-98BA4AF6-DBEE-478D-AEB3-8734396F8EC3Q34729143-4EC29735-ED28-405C-8AE8-20227D0652A6Q34750358-D4189088-8FDF-4AE4-9EC3-0BA5E4FC2952Q34784001-782C6A3D-A13D-401D-A074-61D1A36297A5Q34979983-5699C096-0C89-43DD-987F-4E0743665E2BQ35046178-109DBCC7-78F4-41E7-B6CD-A71D32EC0BAAQ35207107-CD6597DD-8058-47B4-BC8F-3C30F4EEFFF9Q35223677-E0DC6DFB-BFB8-4BCF-A608-852767D2C006Q35575555-CF771C36-E6B0-44EB-B063-93581E372620Q35578068-017B54BD-634A-40C8-891C-A19D4C8B1426Q35680638-E25ADA96-CCB7-4844-AC67-0DEB1256AAADQ35684207-467A69E0-2A2B-42C9-AC94-195B8BC50125Q35754092-CF700B09-B4F5-4B4C-9735-87CD9BF4BF80Q35914585-4410E9E2-E515-4FA5-92F1-F250DE0FAA96Q35946169-8C65B6D8-C4E6-4DC1-8C97-6C7398AB6A3CQ35970190-E558D3A5-7200-400B-AB98-06E1BA9688D6Q36116908-77D49FD9-7F3F-4129-9B5F-2B02E70A9BB6Q36164605-384710CC-3E90-4B0D-BE09-8BF9B8C9482CQ36384120-87389ECB-FB7B-49F9-9F7F-E6C4D061CF83Q36630100-396D107E-35E4-4EE3-AECA-63877B26F67EQ37073554-7212F705-3873-42FB-8841-920C4932B0E0Q37240096-199F28B1-4D80-478D-9644-DC030FCABD33Q37474532-3CB85810-1622-4940-BE5D-3D5EA0D1D8D3Q37542235-90C7730C-0AC1-4272-ACDC-47937FC29986
P2860
Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@ast
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@en
type
label
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@ast
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@en
prefLabel
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@ast
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@en
P2093
P2860
P356
P1476
Mesenchymal cell targeting by ...... joint and intestinal diseases.
@en
P2093
Dimitris L Kontoyiannis
Dirk Elewaut
Maria Apostolaki
Peggy Jacques
P2860
P304
P356
10.1084/JEM.20070906
P407
P577
2008-02-04T00:00:00Z